Grandeur Peak Global Advisors LLC increased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 8.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,250 shares of the medical research company’s stock after acquiring an additional 1,000 shares during the period. Grandeur Peak Global Advisors LLC’s holdings in Edwards Lifesciences Corporation were worth $1,567,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of EW. Van ECK Associates Corp lifted its stake in Edwards Lifesciences Corporation by 7.8% during the 1st quarter. Van ECK Associates Corp now owns 3,253 shares of the medical research company’s stock worth $306,000 after acquiring an additional 236 shares in the last quarter. Edge Asset Management Inc. lifted its stake in Edwards Lifesciences Corporation by 12.2% during the 1st quarter. Edge Asset Management Inc. now owns 223,187 shares of the medical research company’s stock worth $20,995,000 after acquiring an additional 24,201 shares in the last quarter. Teachers Advisors LLC lifted its stake in Edwards Lifesciences Corporation by 26.6% during the 1st quarter. Teachers Advisors LLC now owns 835,393 shares of the medical research company’s stock worth $78,585,000 after acquiring an additional 175,457 shares in the last quarter. TIAA CREF Investment Management LLC lifted its stake in Edwards Lifesciences Corporation by 32.3% during the 1st quarter. TIAA CREF Investment Management LLC now owns 1,717,227 shares of the medical research company’s stock worth $161,540,000 after acquiring an additional 419,266 shares in the last quarter. Finally, Bridgewater Associates LP acquired a new position in Edwards Lifesciences Corporation during the 1st quarter worth about $4,272,000. 82.12% of the stock is currently owned by hedge funds and other institutional investors.
Edwards Lifesciences Corporation (NYSE EW) traded down 0.11% on Thursday, reaching $110.35. The company had a trading volume of 267,724 shares. The firm has a market capitalization of $23.45 billion, a PE ratio of 42.28 and a beta of 0.62. Edwards Lifesciences Corporation has a 12 month low of $81.12 and a 12 month high of $121.45. The stock has a 50 day moving average of $111.58 and a 200 day moving average of $111.24.
Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $839.16 million. During the same quarter in the prior year, the firm posted $0.76 earnings per share. Edwards Lifesciences Corporation’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, analysts anticipate that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.
Several equities analysts recently issued reports on the company. Bank of America Corporation increased their target price on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, July 27th. BidaskClub lowered Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Cowen and Company reaffirmed a “buy” rating and issued a $135.00 price target on shares of Edwards Lifesciences Corporation in a research report on Thursday. SunTrust Banks, Inc. increased their price target on Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a research report on Monday, July 17th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $155.00 price target (up previously from $150.00) on shares of Edwards Lifesciences Corporation in a research report on Sunday, July 30th. Seven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Edwards Lifesciences Corporation has a consensus rating of “Buy” and an average price target of $120.75.
TRADEMARK VIOLATION NOTICE: This article was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.themarketsdaily.com/2017/10/12/grandeur-peak-global-advisors-llc-boosts-position-in-edwards-lifesciences-corporation-ew.html.
In other Edwards Lifesciences Corporation news, VP Catherine M. Szyman sold 4,681 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $115.78, for a total transaction of $541,966.18. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the company’s stock in a transaction that occurred on Friday, July 28th. The shares were sold at an average price of $114.68, for a total value of $607,804.00. The disclosure for this sale can be found here. Insiders have sold 182,201 shares of company stock worth $20,768,154 in the last 90 days. 2.13% of the stock is currently owned by insiders.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.